Summary
Dexamethasone for antiemetic therapy is typically administered with anticancer drugs such as cisplatin. We previously reported that cisplatin upregulates the muscle-specific E3 ubiquitin ligase genes, namely muscle ring-finger protein 1 (MuRF1) and atrophy gene-1 (atrogin-1), and promotes muscle atrophy in mice. It is well known that dexamethasone causes upregulation of MuRF1 and Atrogin-1 expression in skeletal muscles.
Although it is speculated that a combination of dexamethasone and cisplatin worsens muscle atrophy, there are no reports based on research. We thereby investigated the effects of cisplatin and dexamethasone, alone or in combination, on the expression of MuRF1 and Atrogin-1 in murine skeletal muscles and C2C12 myotubes. Mice were intraperitoneally injected with cisplatin or the vehicle control once daily for 4 days.
Dexamethasone or the vehicle control was subcutaneously administered 30 minutes prior to the administration of cisplatin. Dexamethasone enhanced MuRF1 and Atrogin-1 gene expression upregulated by cisplatin in murine quadriceps muscles and C2C12 myotubes. Cisplatin-caused upregulation of myostatin and downregulation of IGF-1 gene expression were also enhanced by co-administration of dexamethasone in murine quadriceps muscles and C2C12 myotubes. This study shows that the combination treatment of cisplatin and dexamethasone exacerbated muscle atrophy in mice. Therefore, this treatment regimen might exacerbate muscle atrophy in cancer patients.
K E Y W O R D S
chemotherapy, cisplatin, dexamethasone, muscle atrophy, skeletal muscle play primary roles in loss of muscle mass and in the downregulation of muscle-specific genes, and MuRF1 and Atrogin-1 are now considered specific markers in skeletal muscle atrophy. Dexamethasone, a glucocorticoid, enhances protein degradation and induces MuRF1 and Atrogin-1 expression in mammalian myotube cultures 5, 8 and mammalian skeletal muscles. 5 This evidence suggests that the upregulation of MuRF1 and Atrogin-1 genes involved in the ubiquitin-proteasome proteolytic pathway contributes to the onset of muscle atrophy under many catabolic conditions and in dexamethasone-exposed myotubes. 7 Glucocorticoid-induced myopathy is common and troublesome at times, impacting significantly on the quality of life of cancer patients receiving steroids such as dexamethasone. Clinical recognition is important since steroid myopathy can lead to increased morbidity and may be reversible with reduction or discontinuation of steroids. 9 Although several molecules directly produced by tumours that contribute to skeletal muscle impairment have been identified, [10] [11] [12] the detailed influence of cisplatin on skeletal muscles remains unknown. We previously reported that cisplatin increased in MuRF1 and
Atrogin-1 gene and protein expression, and consequently promoted muscle atrophy in mice. Furthermore, cisplatin significantly reduces both Akt and Forkhead box O3a (Foxo3a) phosphorylation in mice, so that augmenting the increases in expression of MuRF1 and Atrogin-1.
Cancer-associated cachexia is a severe contributing factor to reduced quality of life and mortality in patients with cancer. Martin et al. recently reported that skeletal muscle depletion is a prognostic factor in cancer patients. 13 Progressive muscle atrophy 14 is considered a pathophysiological reflection of the wasting process related to changes in several metabolic pathways in patients with cancer.
15
Therefore, prevention of the skeletal muscle mass loss in patients receiving cancer chemotherapy is critical important.
Cisplatin and dexamethasone cause muscle atrophy as mentioned above. Although it is speculated that a combination of these therapies worsens muscle atrophy, there are no findings based on research. The present study therefore investigates the effects of cisplatin and dexamethasone, either alone or in combination, on the expression of MuRF1 and Atrogin-1 in murine skeletal muscles and C2C12 myotubes.
| RE SULTS
Body weight significantly decreased in cisplatin-treated mice compared with control mice, and cisplatin-induced change in body weight was not affected by co-administration with dexamethasone ( Figure 1A ). Quadriceps muscle mass also significantly decreased in mice treated with cisplatin compared with the control, and this effect was significantly exacerbated by co-administration with dexamethasone ( Figure 1B) .
We analysed the effect of cisplatin and dexamethasone on morphometric parameters. Myofiber diameter significantly decreased in quadriceps muscles in cisplatin-treated mice compared to control mice, and this effect was significantly enhanced by co-administration with dexamethasone ( Figure. 1C-G).
MuRF1 and Atrogin-1 gene expression levels were examined using qRT-PCR. MuRF1 and Atrogin-1 gene expression levels sig- 
| D ISCUSS I ON
In the present report, we show that cisplatin-induced muscle at- Recently, it has been reported that the IGF-1/PI3K/Akt signaling pathway inhibits Mstn/Smads signalling. 31 Thus, the crosstalk between IGF-1-PI3K-Akt-p70 S6 kinase signaling and Mstn-Smads signaling pathway might also be important in muscle atrophy.
In conclusion, cancer-associated cachexia is a multi-factorial, systemic syndrome that negatively impacts treatment response,
survival, and quality of life. Cachexia is characterized by excessive depletion of skeletal muscle mass. In the present study, we have demonstrated that the combination treatment with cisplatin and the antiemetic agent dexamethasone exacerbated muscle atrophy.
Therefore, attention to muscle atrophy might be needed, although dexamethasone is useful for antiemetic therapy in cancer chemotherapy that uses cisplatin.
| MATERIAL S AND ME THODS

| Animals
Male C57BL/6J mice (Tokyo Laboratory Animals Science Co., Ltd., Tokyo, Japan) aged 8-9 weeks were used in this study. They were F I G U R E 2 Effects of Cis (3 mg/kg, i.p.; Cis3) and Dex (10 mg/kg, s.c.; Dex10) on the gene expression of MuRF1 (A), Atrogin-1 (B), myostatin (Mstn; E), and insulin-like growth factor-1 (IGF-1; F) in mouse quadriceps muscles. Each column represents the mean ± SEM from 
| Treatment protocol
Animals were injected with a cisplatin (3 mg/kg, ip) or its vehicle (sa- 
| Histology
Quadriceps muscles from cisplatin-or control-treated mice were analysed using hematoxylin and eosin (HE) staining as described previously. 17 The diameters of the myofibers of the quadriceps muscle sections were measured in using a light microscope and ImageJ software (NIH) as previously described. 17 At least 60 fibres per animal were measured. Each column represents the mean ± SEM of three independent experiments, respectively (D and E; Control: N = 3, Cis15: N = 3, Dex3: N = 3 and Cis15 + Dex3: N = 3). *P < 0.05, **P < 0.01, and ***P < 0.001 vs Control (Saline + Saline). # P < 0.05 and ### P < 0.001 vs Cis15. $$$ P < 0.001 vs Dex3
| Quantitative RT-PCR
mRNA levels were investigated using reverse transcriptase (RT)-real-time PCR as previously described. 17 In brief, the total RNA was extracted from tissues using TRI Reagent™ (Sigma-Aldrich).
cDNA was prepared from total the RNA using a QuantiTect Reverse
Transcriptase Kit (Qiagen, Hilden, Germany). The reaction mixture was analysed using PCR with sense (forward) and anti-sense (reverse) primers (Table 1) 
| Western blotting
Preparation of protein samples and Western blot were performed as previously described. 17 The following primary antibodies were used: 
| Statistical analysis
Data are expressed as mean ± SEM, and statistical analysis was performed by unpaired Student's t-test or ANOVA followed by Bonferroni/Dunn or Dunnett's post-hoc tests using the Prism 5 programme (GraphPad Software for Science, San Diego, CA, USA).
P < 0.05 was considered statistically significant. 
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